Whether your disinfectant needs TGA listing comes down to the claims you make. Here's how specific and non-specific claims decide the regulatory pathway — and where brands slip up.

Same bottle, different rules

Two disinfectants can share an identical formula and yet face completely different regulatory obligations in Australia. The difference isn't the chemistry — it's the claim. What you say your product kills, and how, is what determines how the TGA regulates it. Get the claim right and the pathway follows logically; get it wrong and you can find yourself either over-regulated or, more dangerously, non-compliant.

Specific claims vs non-specific claims

The dividing line runs through the kind of antimicrobial claim you make.

Specific claims — activity against viruses, named organisms, or sporicidal, fungicidal, tuberculocidal or virucidal action — are the higher bar. A product making specific claims must be Listed on the ARTG before it can be supplied, and the claims must be validated by testing (the TGA Disinfectant Test or an accepted equivalent).

Non-specific claims — general antibacterial action against the standard battery of test organisms — sit in the exempt category. "Exempt" is the word that trips brands up, because it does not mean unregulated. An exempt disinfectant still has to comply with TGO 104 (the disinfectants standard), hold satisfactory evidence for its claims, and carry a compliant label. It simply doesn't require an individual ARTG listing.

And at the far end, some products — for example those with claims limited to moulds only — are excluded goods, outside TGA regulation altogether.

The practical upshot: the exact wording on your label and marketing decides which of these worlds you're in.

The residual-efficacy trap

One area catches brands out more than most: residual or ongoing protection claims — "keeps killing germs for 24 hours," and similar. Since TGO 104 was updated to define "residual activity," any claim of ongoing efficacy must meet specific methodologies, acceptance criteria and maximum claim durations set out in the TGA's instructions for disinfectant testing.

In other words, you can't simply assert lasting protection — you need the data, generated the right way, to support the exact duration you claim. Residual-efficacy claims made without that backing are a common source of non-compliance.

COVID-19 claims

Claims against viruses, including SARS-CoV-2, are specific claims — so a product marketed as effective against COVID-19 needs to be Listed, with supporting virucidal testing. The TGA accepts certain surrogate viruses in lieu of live SARS-CoV-2 for that testing.

Where brands most often slip up

  • Making a specific claim without listing — the single most serious error; the product is being supplied unlawfully.
  • Assuming "exempt" means "unregulated" — TGO 104, evidence and labelling still apply.
  • Overstating residual protection without the methodology and data to support the claimed duration.
  • Label claims that don't match the pathway — marketing that promises more than the product's regulatory status entitles it to say.

What to do

Decide your claims deliberately, understand which pathway each one triggers, hold the evidence to back them, and make sure the label matches — all before you go to market. If a claim would drag you into a more onerous pathway than you want, sometimes the right move is to dial the claim back; if a strong claim is central to the product, plan for the listing and testing it requires.

How Engel Hellyer & Partners can help

Disinfectants are one of our core areas — we've submitted more than 20 disinfectant applications to the TGA, plus many more label and claim reviews. We advise on exactly which claims trigger which pathway, prepare ARTG listings, review efficacy data and labels against TGO 104, and — where you'd rather avoid disinfectant claims entirely — help present a product for cleaning-only use.

If you're developing a disinfectant or unsure whether your current claims match your regulatory status, we're happy to take a look.

This article is general information only and does not constitute regulatory advice for any specific product. Requirements change; confirm the current position before acting.

Further reading

Primary guidance from the Therapeutic Goods Administration:

‍

Written by 
Dr Gloria Mao
Has over 15 years of international experience in the food, complementary medicine and cosmetic industries. She received her doctorate from the University of California, Los Angeles in Toxicology and Pharmacology. She received her Masters of Arts in Biochemistry and Molecular Biology from Harvard University and her Bachelors of Science in Biochemistry from the University of Illinois.